You may also like

Candid Therapeutics Emerges with $370M to Develop T-Cell Engagers for Autoimmunity
Marea, Incubated by Third Rock, Gets $190M to Take Aim at Remnant Cholesterol
Clasp, Backed by Catalio, Third Rock & Novo, Gets $150M for Specific T-cell Engagers
Investing in the Future of Medicine: Reid Huber on The Long Run